CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Baricitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02576938
NCT02576938Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company·interventional·Posted Oct 15, 2015·Updated Jun 17, 2020

In Brief

A Phase 2 clinical trial evaluating Baricitinib, Placebo, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 124 participants across 13 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesJapan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 15, 2015
Enrollment StartFeb 1, 2016
Primary CompletionFeb 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.7 years ago

Interventions

Baricitinibdrug

Administered orally

Placebodrug

Administered orally

Triamcinolone (Optional)drug

Administered topically